16800 West Twelve Mile Road
Suite 201, Southfield, MI 48076

Spinning Globe

Products and Pipeline

Housey Pharma focuses upon the creation and discovery of new prescription and non-prescription medicines to treat rapidly and uniformly fatal human diseases, as well as for certain chronic diseases for which current therapies are inadequate to achieve a complete cure or durable long-term remission.  We also develop advanced drug creation and discovery technologies, an area in which our company's scientists have a proven track record.

Technology Licensing Programs

Areas of Application

Patent Status

Countries With Issued or Pending Patents

Development Stage

Commercially Licensed and Marketed

Cell‐Based Assay Technologies Invented at Housey Pharma

Early

Late

Cell‐Based Lead Optimization

Drug Discovery for All Diseases

ISSUED

> 20

Modulators of Drug‐Resistant Mutants (Theramuteins) in All Forms of Cancer.

Drug Discovery In Oncology

ISSUED

> 20

Inlicensed/Outlicensed Technology

Early

Late

Drug‐Resistant Bcr‐Abl Mutants

CML and certain other Leukemias

ISSUED

> 10

Prescription Track
Therapeutic Compounds

Indication(s)

Clinical Development Phase

Commercially Marketed

Diabetes

Pre‐Clinical

Phase 1

Phase 2

Phase 3

HP‐211 (Botanical IRS‐2 Activator)

Type 2 Diabetes

HP‐508 (Beta Cell Regeneration)

Type 1 Diabetes

HP‐233 (Small Molecule IRS‐2 Activator)

Type 2 Diabetes

HP‐038 (Small Molecule IRS‐2 Activator)

Type 2 Diabetes

Obesity and Steatosis

Pre‐Clinical

Phase 1

Phase 2

Phase 3

Novel Hormonal Target

Obesity, NASH, and Steatosis

Oncology

Pre‐Clinical

Phase 1

Phase 2

Phase 3

HP‐2 and HP‐3 Series Inhibitors for Selected Protein Kinase Targets

Drug‐Resistant Cancers

Products Available
Without a Prescription

Indication(s)

Development Phase

Commercially Marketed

Pre‐Clinical

Clinical

Axulin® (tablet formulation)
First approval in Canada1

1Approved on May 1, 2014. Health Canada has classified Axulin® as a Natural Health Product and has assigned to it Natural Product Number (NPN) # 80050544.

Nutritional Support for Diabetes, Metabolic Syndrome, Polycystic Ovarian Syndrome (PCOS) Pre‐Diabetes

Canada

U.S.

Axulin Package

Future Commercial Approvals
Pending in:
Mexico
Targeted in 2021:
Selected countries in the European Union